Falling Walls Falling Walls Science Summit 2023

Breaking the Wall to Better Control of Tuberculosis

Stefan Kaufmann

Life Sciences

The nominating institution Max Planck Society on the breakthrough:

Kaufmann’s work on Tuberculosis shows how basic research can lead to the rational design of novel interventions. The vaccine VPM1002 has been licensed to Vakzine Projekt-Management, Hannover / Serum Institute India, Pune. It has successfully completed phase-I clinical trials in adults and a phase-II clinical trial in neonates, demonstrating safety and immunogenicity of it in diff. age groups and regions. A phase-II clinical trial in HIV-exposed / unexposed neonates has been successfully completed.

Bio-Tech, Global Health, Diseases of Inequality

Stefan Kaufmann

Max Planck Institute for Infection Biology

Professor Stefan H.E. Kaufmann is founding director & director emeritus at the Max Planck Institute for Infection Biology in Berlin. He is also a faculty fellow at Hagler Institute for Advanced Study, Texas A&M University, College Station, professor of microbiology & immunology at Charité, and former president of German Society for Immunology. His breakthrough finding is the rational design and development of a vaccine tested for protective activity against tuberculosis and Covid-19, and as therapy for bladder cancer in advanced clinical trials.

Further Activities to have a look at